Objective: Our aim was to evaluate the biopsy quality of upper urinary tract urothelial transitional cell carcinoma with a new biopsy forceps (BIGopsy®, Cook Medical) compared to a classic biopsy forceps (Piranha®, Boston Scientific). Patients and Methods: From December 2009 to December 2011, 20 patients with upper urinary tract urothelial transitional cell carcinoma underwent conservative treatment endoscopically. All lesions were evaluated and biopsied with 3 Fr cup forceps using both types of forceps (BIGopsy and Piranha). A single pathologist blindly analyzed the specimens in order to determine the optimal biopsy for each patient. Specimen histopathology results were graded; however, they were staged if the lamina propria was not invaded (T1) or if the tumor was detected at the lamina propria (T1+). Results: Of the 20 upper urinary tract lesions, 12 (60%) were in the renal pelvis, 3 (15%) in the upper calyx, 1 (5%) in the middle calyx, 1 (5%) in the lower calyx, 1 (5%) in the upper third of the ureter and 2 (10%) in the middle third of the ureter. We did not detect T1 in all biopsies. One patient had no valid biopsies by both forceps. A diagnosis of urothelial carcinoma was made in 17 BIGopsy biopsies compared to 7 Piranha biopsies. Conclusion: Despite the limited number of cases, our study demonstrated the advantage of the new forceps (BIGopsy) in obtaining a valid biopsy of upper urinary tract urothelial tumors. Therefore, we recommend it in evaluating this pathology for optimal treatment.

Keywords:
Flexible ureterorenoscopy, Upper urinary tract urothelial tumor, Retrograde biopsy, Biopsy forceps, Ureteroscopic biopsy
1.
Huffman JL, Morse MJ, Herr HW, Sogani PC, Whitmore WF, Fair WR: Ureteropyeloscopy: the diagnostic and therapeutic approach to upper tract urothelial tumors. World J Urol 1985;3:58-63.
2.
Hara I, Hara S, Miyake H, Nomi M, Gotoh A, Kawabata G, Arakawa S, Kamidono S: Usefulness of ureteropyeloscopy for diagnosis of upper urinary tract tumors. J Endourol 2001;15:601-605.
3.
Abdel-Razzak OM, Ehya H, Cubler-Goodman A, Bagley DH: Ureteroscopic biopsy in the upper urinary tract. Urology 1994;44:451-457.
4.
Tawfiek E, Bibbo M, Bagley DH: Ureteroscopic biopsy: technique and specimen preparation. Urology 1997;50:117-119.
5.
Kulp DA, Bagley DH: Does flexible ureteropyeloscopy promote local recurrence of transitional cell carcinoma? J Endourol 1994;8:111-113.
6.
Lam JS, Gupta M: Ureteroscopic management of upper tract transitional cell carcinoma. Urol Clin North Am 2004;31:115-128.
7.
Chen GL, El-Gabry EA, Bagley DH: Surveillance of upper urinary tract transitional cell carcinoma: the role of ureteroscopy, retrograde pyelography, cytology and urinalysis. J Urol 2000;164:1901-1904.
8.
Keeley FX, Kulp DA, Bibbo M, McCue PA, Bagley DH: Diagnostic accuracy of ureteroscopic biopsy in upper tract transitional cell carcinoma. J Urol 1997;157:33-37.
9.
Kiriyama T, Hironaka H, Fukuda K: Six years of experience with retrograde biopsy of intraureteral carcinoma using the Dormia stone basket. J Urol 1976;116:308-310.
10.
Guarnizo E, Pavlovich CH, Seiba M, Carlson DZ, Vaugham ED, Sosa RE: Ureteroscopic biopsy of upper tract urothelial carcinoma: improved diagnostic accuracy and histopathological considerations using a multi-biopsy approach. J Urol 2000;163:52-55.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.